TissueGene Recognized During Maryland Commerce, State Departments' Week-Long Trade Mission To South Korea

The reception featured a check presentation by First Lady Yumi Hogan and Maryland Deputy Secretary of Commerce Ben Wu to TissueGene, Inc., a Rockville-based advanced cell therapies company that has developed a first-in-class cell and gene therapy targeting osteoarthritis (OA) of the knee. The $750,000 grant from Maryland's Stem Cell Research Fund, administered by TEDCO, was announced earlier this year and will help the company to successfully conduct Phase III clinical trials in the United States for its product Invossa™, a first-in-class cell and gene therapy targeting OA of the knee through a single intra-articular injection. TissueGene has designed its Phase III program to seek a disease-modifying osteoarthritis drug (DMOAD) designation for Invossa from the U.S. Food and Drug Administration (FDA)—potentially making Invossa the first therapy to receive a DMOAD label. In July 2017, Kolon Life Science, Inc., TissueGene's exclusive licensee for Asia, received South Korean MFDS marketing approval for Invossa-K Inj.

About TissueGene, Inc.
TissueGene, Inc., is an advanced cell therapies company that has developed a first-in-class cell and gene therapy targeting OA of the knee. TissueGene's lead product, Invossa™, is an allogeneic cell and gene therapy. The Company is preparing for Phase III clinical trials in the U.S. under a Special Protocol Assessment (SPA) agreement reached with the U.S. Food and Drug Administration (FDA). Information about the trials can be found at the National Institutes of Health registry, www.clinicaltrials.gov.  For additional information about TissueGene, Inc., please visit www.tissuegene.com.

SOURCE TissueGene, Inc.

Related Links

http://www.tissuegene.com